JP2003526659A - 癌の治療のためのカンプトテシンもしくはカンプトテシン誘導体およびアルキル化剤を含んで成る組成物 - Google Patents
癌の治療のためのカンプトテシンもしくはカンプトテシン誘導体およびアルキル化剤を含んで成る組成物Info
- Publication number
- JP2003526659A JP2003526659A JP2001566630A JP2001566630A JP2003526659A JP 2003526659 A JP2003526659 A JP 2003526659A JP 2001566630 A JP2001566630 A JP 2001566630A JP 2001566630 A JP2001566630 A JP 2001566630A JP 2003526659 A JP2003526659 A JP 2003526659A
- Authority
- JP
- Japan
- Prior art keywords
- camptothecin
- cyclophosphamide
- alkylating agent
- effective amount
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 36
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title claims abstract description 32
- 229940100198 alkylating agent Drugs 0.000 title claims abstract description 22
- 239000002168 alkylating agent Substances 0.000 title claims abstract description 22
- 229940127093 camptothecin Drugs 0.000 title claims abstract description 18
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 title claims abstract description 15
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title claims description 10
- 201000011510 cancer Diseases 0.000 title abstract description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229960004397 cyclophosphamide Drugs 0.000 claims abstract description 38
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims abstract description 15
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims abstract description 14
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 11
- 229960001924 melphalan Drugs 0.000 claims abstract description 7
- 229960003901 dacarbazine Drugs 0.000 claims abstract description 5
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 201000008274 breast adenocarcinoma Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 description 16
- 231100000252 nontoxic Toxicity 0.000 description 13
- 230000003000 nontoxic effect Effects 0.000 description 13
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000022534 cell killing Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- -1 L-sarcolicin Chemical compound 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 2
- 229940098174 alkeran Drugs 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229910052757 nitrogen Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101150073133 Cpt1a gene Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- FDKXTQMXEQVLRF-UHFFFAOYSA-N dacarbazine Chemical compound CN(C)N=NC=1NC=NC=1C(N)=O FDKXTQMXEQVLRF-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19000700P | 2000-03-17 | 2000-03-17 | |
| US60/190,007 | 2000-03-17 | ||
| PCT/EP2001/003500 WO2001068066A2 (en) | 2000-03-17 | 2001-03-14 | A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003526659A true JP2003526659A (ja) | 2003-09-09 |
| JP2003526659A5 JP2003526659A5 (enExample) | 2006-01-05 |
Family
ID=22699678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001566630A Withdrawn JP2003526659A (ja) | 2000-03-17 | 2001-03-14 | 癌の治療のためのカンプトテシンもしくはカンプトテシン誘導体およびアルキル化剤を含んで成る組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6548488B2 (enExample) |
| EP (1) | EP1267873A2 (enExample) |
| JP (1) | JP2003526659A (enExample) |
| AR (1) | AR027677A1 (enExample) |
| AU (1) | AU2001252235A1 (enExample) |
| WO (1) | WO2001068066A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006032136A1 (en) * | 2004-09-20 | 2006-03-30 | British Columbia Cancer Agency Branch | Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin |
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| WO2007092646A2 (en) * | 2006-02-09 | 2007-08-16 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| US7671067B2 (en) | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
| KR20090108082A (ko) | 2007-02-09 | 2009-10-14 | 엔존 파마슈티컬즈, 인코포레이티드 | 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399276A (en) | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
| US4473692A (en) | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| JPS58154582A (ja) | 1982-03-10 | 1983-09-14 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体およびその製造法 |
| US4981968A (en) | 1987-03-31 | 1991-01-01 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
| CA1332413C (en) | 1987-06-25 | 1994-10-11 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| US5004758A (en) | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| JPH0615547B2 (ja) | 1988-01-20 | 1994-03-02 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体 |
| DE69209969T2 (de) | 1991-10-29 | 1996-09-12 | Glaxo Wellcome Inc | Wasserlösliche Camptothecinderivate |
| US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
| US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
| GB9510716D0 (en) | 1995-05-26 | 1995-07-19 | Pharmacia Spa | Substituted camptothecin derivatives and process for their preparation |
| US5670500A (en) | 1995-05-31 | 1997-09-23 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
| US5663177A (en) | 1995-05-31 | 1997-09-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
| US6191119B1 (en) | 1999-10-15 | 2001-02-20 | Supergen, Inc. | Combination therapy including 9-nitro-20(S)-camptothecin |
-
2001
- 2001-03-07 US US09/799,615 patent/US6548488B2/en not_active Expired - Fee Related
- 2001-03-14 AU AU2001252235A patent/AU2001252235A1/en not_active Abandoned
- 2001-03-14 JP JP2001566630A patent/JP2003526659A/ja not_active Withdrawn
- 2001-03-14 EP EP01925510A patent/EP1267873A2/en not_active Withdrawn
- 2001-03-14 WO PCT/EP2001/003500 patent/WO2001068066A2/en not_active Ceased
- 2001-03-16 AR ARP010101256A patent/AR027677A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001252235A1 (en) | 2001-09-24 |
| WO2001068066A3 (en) | 2002-06-20 |
| US20010056082A1 (en) | 2001-12-27 |
| US6548488B2 (en) | 2003-04-15 |
| EP1267873A2 (en) | 2003-01-02 |
| AR027677A1 (es) | 2003-04-09 |
| WO2001068066A2 (en) | 2001-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6960596B2 (en) | Composition comprising camptothecin or a comptothecin derivative and a platin derivative for the treatment of cancer | |
| RU2508110C2 (ru) | КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek | |
| JPH07501079A (ja) | 組合せ化学療法 | |
| CN100411628C (zh) | 空间位阻的铂配位化合物与非铂抗癌剂的组合及其应用 | |
| Dahut et al. | Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. | |
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| EP2435041A1 (en) | Therapeutic combination comprising a plk1 inhibitor and an antineoplastic agent | |
| JP2002543112A (ja) | アントラサイクリン誘導体を含有する配合製剤 | |
| AU2019362050B2 (en) | Combinations for immune-modulation in cancer treatment | |
| JP2002507571A (ja) | アントラサイクリン誘導体とカンプトテシン誘導体の相乗組合せを含有する抗腫瘍組成物 | |
| CZ302451B6 (cs) | Protirakovinová farmaceutická kombinace | |
| JP2006504721A (ja) | 治療剤に対する乳癌耐性タンパク質（ｂｃｒｐ）−介在耐性を阻害するためのイマチニブ（グリベック、ｓｔｉ−５７１）の使用 | |
| JP2003526659A (ja) | 癌の治療のためのカンプトテシンもしくはカンプトテシン誘導体およびアルキル化剤を含んで成る組成物 | |
| US6562834B2 (en) | Combination comprising camptothecin and a stilbene derivative for the treatment of cancer | |
| AU2002216029A1 (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer | |
| US20030195161A1 (en) | Composition comprising camptothecin or a camptothecin derivative and a topoisomerase II inhibitor for the treatment of cancer | |
| JPH06505487A (ja) | 食道癌の治療用医薬組成物 | |
| US20040204435A1 (en) | Alternating treatment with topoisomerase I and topoisomerase II inhibitors | |
| EP1716852A1 (en) | A composition comprising campothecin or a campothecin derivative and an alkylating agent for the treatment of cancer | |
| JPH06505740A (ja) | 卵巣癌の治療用医薬組成物 | |
| Flaherty et al. | The clinical development of lurtotecan: experience with water-soluble and liposomal forms | |
| ZA200302552B (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer. | |
| NZ740252A (en) | Antitumor agent including low-dose irinotecan hydrochloride hydrate | |
| NZ740252B2 (en) | Antitumor agent including low-dose irinotecan hydrochloride hydrate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050824 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050824 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070627 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20071226 |